



TREATING ADULT PATIENTS WITH OCULAR MYASTHENIA GRAVIS?

Consider referring your patient
to an interventional study:

"A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis"

The investigational study drug, efgartigimod PH20 SC, is not approved by the FDA for the treatment of patients with ocular myasthenia gravis as efficacy and safety have not been established.

CT.gov: NCT06558279

